SenesTech, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that SenesTech, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $600.0K | Mar 29, 2022 |
| FY2021 | Dec 31, 2020 | $282.0K | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $143.0K | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $297.0K | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | $52.0K | Mar 29, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.22M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $1.86M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $1.19M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $1.02M | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $600.0K | Mar 17, 2023 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $52.0K | Mar 30, 2018 |
| FY2017 | Dec 31, 2016 | $318.0K | Mar 30, 2018 |
| FY2016 | Dec 31, 2015 | $241.0K | Nov 6, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.39M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $1.00M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $539.0K | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $464.0K | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $244.0K | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | $1.0K | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $42.0K | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $56.0K | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | $7.0K | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $318.0K | Mar 30, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($6.38M) | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | ($6.18M) | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | ($7.71M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | ($9.70M) | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | ($8.27M) | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | ($8.37M) | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | ($10.02M) | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | ($11.91M) | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | ($12.29M) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($10.80M) | Mar 30, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($6.51M) | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | ($6.25M) | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | ($7.73M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | ($9.67M) | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | ($8.93M) | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | ($7.93M) | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | ($10.29M) | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | ($11.88M) | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | ($12.32M) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($10.52M) | Mar 30, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.70M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $1.71M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $1.23M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $1.86M | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $1.95M | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | $1.49M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $1.91M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $2.40M | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | $3.19M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $2.71M | Mar 30, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($5.75M) | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | ($6.03M) | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | ($7.57M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | ($8.58M) | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | ($7.78M) | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | ($7.11M) | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | ($8.06M) | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | ($9.13M) | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | ($9.32M) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($6.70M) | Mar 30, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $138.0K | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $84.0K | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $149.0K | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $174.0K | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $100.0K | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | $114.0K | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $71.0K | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $239.0K | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | $898.0K | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $57.0K | Mar 30, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.84M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $3.28M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $7.29M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $6.78M | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $11.50M | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | $6.02M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $4.98M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $7.75M | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | $9.32M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $12.87M | Mar 30, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.28M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $767.0K | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $942.0K | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $1.50M | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $1.47M | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | $2.14M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $2.41M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $1.44M | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | $1.80M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $2.04M | Mar 30, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.57M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $2.51M | Mar 13, 2026 |
| FY2025 | Dec 31, 2023 | $6.35M | Mar 13, 2026 |
| FY2024 | Dec 31, 2022 | $5.28M | Mar 13, 2025 |
| FY2023 | Dec 31, 2021 | $10.04M | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $3.88M | Mar 17, 2023 |
| FY2021 | Dec 31, 2019 | $2.57M | Mar 29, 2022 |
| FY2020 | Dec 31, 2018 | $6.31M | Mar 29, 2021 |
| FY2019 | Dec 31, 2017 | $7.52M | Mar 17, 2020 |
| FY2018 | Dec 31, 2016 | $10.83M | Mar 29, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($142.48M) | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | ($136.10M) | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | ($129.91M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | ($122.20M) | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | ($112.51M) | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | ($104.24M) | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | ($95.87M) | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | ($85.84M) | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | ($73.60M) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($61.31M) | Mar 30, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.58M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $1.31M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $5.40M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $4.78M | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $9.33M | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | $3.64M | Mar 29, 2022 |
| FY2021 | Dec 31, 2019 | $1.94M | Mar 29, 2022 |
| FY2020 | Dec 31, 2018 | $4.92M | Mar 29, 2021 |
| FY2019 | Dec 31, 2017 | $2.10M | Mar 17, 2020 |
| FY2018 | Dec 31, 2016 | $11.83M | Mar 29, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $768.0K | Mar 30, 2018 |
| FY2017 | Dec 31, 2016 | $183.0K | Mar 30, 2018 |
| FY2016 | Dec 31, 2015 | $477.0K | Nov 6, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | (8) | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | (115) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | (148) | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | (14) | Mar 17, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | (8) | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | (115) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | (148) | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | (14) | Mar 17, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 5.22M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | 1.04M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | 514,003 | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | 67,472 | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | 610,364 | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | 5.10M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | 1.41M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | 1.17M | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | 16.40M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | 10.16M | Mar 30, 2018 |